WNK Kinase Inhibitor

WNK463 is an orally bioavailable pan-With-No-Lysine (K) (WNK)-kinase inhibitor with IC_50s of 5 nM, 1 nM, 6 nM, and 9 nM for WNK1, WNK2, WNK3, and WNK4, respectively.

WNK-IN-11 is an allosteric With-No-Lysine (WNK) kinase inhibitor, with an IC₅₀ of 4 nM for WNK1.

WNK-IN-1 (compound 7) is a ATP noncompetitive With-No-Lysine (WNK) kinase inhibitor (IC₅₀=95 nM). WNK-IN-1 can be used to regulate cardiovascular homeostasis.

WNK2-IN-1 is a WNK2 inhibitor. WNK2-IN-1 inhibits the kinase activity of recombinant WNK2 in a dose-dependent manner, and simultaneously partially inhibits WNK3 and WNK4. WNK2-IN-1 modulates WNK2-SPAK downstream signaling by inhibiting WNK2-mediated SPAK phosphorylation, and further suppresses the proinflammatory transcriptional response induced by IL1β. WNK2-IN-1 can be used in studies related to the WNK2 signaling pathway and osteoarthritis.

WNK-IN-11-d₃ is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d₃ is effective at regulating cardiovascular homeostasis.